159 related articles for article (PubMed ID: 17088057)
1. Molecular dynamics simulation of the P2Y14 receptor. Ligand docking and identification of a putative binding site of the distal hexose moiety.
Ivanov AA; Fricks I; Kendall Harden T; Jacobson KA
Bioorg Med Chem Lett; 2007 Feb; 17(3):761-6. PubMed ID: 17088057
[TBL] [Abstract][Full Text] [Related]
2. Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling.
Costanzi S; Mamedova L; Gao ZG; Jacobson KA
J Med Chem; 2004 Oct; 47(22):5393-404. PubMed ID: 15481977
[TBL] [Abstract][Full Text] [Related]
3. GPR17: molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors.
Parravicini C; Ranghino G; Abbracchio MP; Fantucci P
BMC Bioinformatics; 2008 Jun; 9():263. PubMed ID: 18533035
[TBL] [Abstract][Full Text] [Related]
4. Defining the nucleotide binding sites of P2Y receptors using rhodopsin-based homology modeling.
Ivanov AA; Costanzi S; Jacobson KA
J Comput Aided Mol Des; 2006; 20(7-8):417-26. PubMed ID: 17016747
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling of the human P2Y14 receptor: A template for structure-based design of selective agonist ligands.
Trujillo K; Paoletta S; Kiselev E; Jacobson KA
Bioorg Med Chem; 2015 Jul; 23(14):4056-64. PubMed ID: 25868749
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor.
Ko H; Fricks I; Ivanov AA; Harden TK; Jacobson KA
J Med Chem; 2007 May; 50(9):2030-9. PubMed ID: 17407275
[TBL] [Abstract][Full Text] [Related]
7. Molecular recognition in purinergic receptors. 1. A comprehensive computational study of the h-P2Y1-receptor.
Major DT; Fischer B
J Med Chem; 2004 Aug; 47(18):4391-404. PubMed ID: 15317452
[TBL] [Abstract][Full Text] [Related]
8. Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference.
Costanzi S; Joshi BV; Maddileti S; Mamedova L; Gonzalez-Moa MJ; Marquez VE; Harden TK; Jacobson KA
J Med Chem; 2005 Dec; 48(26):8108-11. PubMed ID: 16366591
[TBL] [Abstract][Full Text] [Related]
9. Identification of a carbohydrate recognition motif of purinergic receptors.
Zhao L; Wei F; He X; Dai A; Yang D; Jiang H; Wen L; Cheng X
Elife; 2023 Nov; 12():. PubMed ID: 37955640
[TBL] [Abstract][Full Text] [Related]
10. Modelling the P2Y purinoceptor using rhodopsin as template.
Van Rhee AM; Fischer B; Van Galen PJ; Jacobson KA
Drug Des Discov; 1995 Nov; 13(2):133-54. PubMed ID: 8872457
[TBL] [Abstract][Full Text] [Related]
11. Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor.
Moro S; Hoffmann C; Jacobson KA
Biochemistry; 1999 Mar; 38(12):3498-507. PubMed ID: 10090736
[TBL] [Abstract][Full Text] [Related]
12. The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver.
Mederacke I; Filliol A; Affo S; Nair A; Hernandez C; Sun Q; Hamberger F; Brundu F; Chen Y; Ravichandra A; Huebener P; Anke H; Shi H; Martínez García de la Torre RA; Smith JR; Henderson NC; Vondran FWR; Rothlin CV; Baehre H; Tabas I; Sancho-Bru P; Schwabe RF
Sci Transl Med; 2022 Apr; 14(639):eabe5795. PubMed ID: 35385339
[TBL] [Abstract][Full Text] [Related]
13. Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups.
Das A; Ko H; Burianek LE; Barrett MO; Harden TK; Jacobson KA
J Med Chem; 2010 Jan; 53(1):471-80. PubMed ID: 19902968
[TBL] [Abstract][Full Text] [Related]
14. Structure and ligand-binding site characteristics of the human P2Y11 nucleotide receptor deduced from computational modelling and mutational analysis.
Zylberg J; Ecke D; Fischer B; Reiser G
Biochem J; 2007 Jul; 405(2):277-86. PubMed ID: 17338680
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family.
Abbracchio MP; Boeynaems JM; Barnard EA; Boyer JL; Kennedy C; Miras-Portugal MT; King BF; Gachet C; Jacobson KA; Weisman GA; Burnstock G
Trends Pharmacol Sci; 2003 Feb; 24(2):52-5. PubMed ID: 12559763
[TBL] [Abstract][Full Text] [Related]
16. Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction.
Shim JY; Welsh WJ; Howlett AC
Biopolymers; 2003; 71(2):169-89. PubMed ID: 12767117
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor.
Besada P; Shin DH; Costanzi S; Ko H; Mathé C; Gagneron J; Gosselin G; Maddileti S; Harden TK; Jacobson KA
J Med Chem; 2006 Sep; 49(18):5532-43. PubMed ID: 16942026
[TBL] [Abstract][Full Text] [Related]
18. Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor.
Carter RL; Fricks IP; Barrett MO; Burianek LE; Zhou Y; Ko H; Das A; Jacobson KA; Lazarowski ER; Harden TK
Mol Pharmacol; 2009 Dec; 76(6):1341-8. PubMed ID: 19759354
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological effects mediated by UDP-glucose that are independent of P2Y14 receptor expression.
Scrivens M; Dickenson JM
Pharmacol Res; 2005 Jun; 51(6):533-8. PubMed ID: 15829433
[TBL] [Abstract][Full Text] [Related]
20. UDP-sugars activate P2Y
Abbas ZSB; Latif ML; Dovlatova N; Fox SC; Heptinstall S; Dunn WR; Ralevic V
Vascul Pharmacol; 2018 Apr; 103-105():36-46. PubMed ID: 29253618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
